News - Merck KGaA, Oncology

Filter

Current filters:

Merck KGaAOncology

Popular Filters

1 to 25 of 31 results

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

24-06-2014

Privately-held US biotech company Mersana Therapeutics and EMD Serono, the North America biopharmaceutical…

BiotechnologyEMD SeronoMerck KGaAOncologyResearch

Merck Serono’s Erbitux to be funded by CDF in England for mCRC

28-02-2014

The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux

24-12-2013

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck Serono partners with Spanish research center for cancer drug development

Merck Serono partners with Spanish research center for cancer drug development

19-12-2013

Merck Serono, the biotech division of German life sciences group Merck KGaA, has signed an accord with…

BiotechnologyLicensingMerck KGaAMerck SeronoNorthern EuropeOncologyResearch

Germany’s Merck invests in further research partnerships in Israel

Germany’s Merck invests in further research partnerships in Israel

26-11-2013

German pharma and chemicals firm Merck KGaA says it is increasingly counting on partnerships with Israeli…

BiotechnologyChanBioFinancialMerck KGaAMetabomedNeurologicalOncologyResearchRest of the World

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

08-11-2013

The Brazilian Ministry of Health is managing a series of product development partnerships and the selection…

Anti-Arthritics/RheumaticsBionovisBiotechnologyFinancialMerck KGaAMerck SeronoOncologyProductionSouth America

Merck Serono and Selvita collaborate on cancer research

Merck Serono and Selvita collaborate on cancer research

24-10-2013

Merck Serono and Poland-based biotech firm Selvita have entered into a collaboration to jointly discover…

BiotechnologyMerck KGaAMerck SeronoOncologyResearchSelvita

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield

09-07-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

Merck Serono sets up new platform for cancer therapies innovation

26-06-2013

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck Serono collaborates with China's BeiGene on second-generation BRAF Inhibitor

31-05-2013

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), today (May 31) announced that it has signed…

BeiGeneBeiGene-283BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceutical

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux

23-05-2013

Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

16-05-2013

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), announced detailed results from the randomized…

BiotechnologyL-BLP25Merck KGaAMerck SeronoOncologyPharmaceuticalResearchStimuvax

Merck KGaA's glioblastoma candidate cilengitide fails in Ph III study

25-02-2013

German drug major Merck KGaA (MRK: DE) revealed this morning that the Phase III CENTRIC trial of the…

BiotechnologycilengitideMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck Serono initiation of TH-302 Ph III trial triggers $30 million milestone for Threshold

29-01-2013

Merck Serono, the pharma division of Germany's Merck KGaA (MRK: DE), has initiated the global Phase III…

FinancialMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302Threshold Pharmaceuticals

Merck Serono NSCLC vaccine candidate fails to meet primary endpoint in Ph III

20-12-2012

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Darmstadt, says that the Phase III START…

L-BLP25Merck KGaAMerck SeronoOncologyOncothyreonPharmaceuticalResearchStimuvaxVaccines

News briefs from Threshold, Merck KGaA and GSK

18-09-2012

US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial…

BiotechnologyErbituxEuropeGlaxoSmithKlineMerck KGaAMerck SeronoOncologyPharmaceuticalRegulationResearchSynflorixTH-302Threshold PharmaceuticalsVaccines

Merck Serono gains rights to Ph II cancer drug from Symphogen for up to 475 million euros

06-09-2012

Privately-held Danish drug developer Symphogen A/S announced this morning that it has signed an exclusive…

BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceuticalSym004Symphogen

Merck KGaA acquires rights to PDS Biotech's technology; threatens action in Portugal

10-07-2012

Privately-held US biotech firm PDS Biotechnology says it has entered into an exclusive worldwide licensing…

BiotechnologyEuropeFinancialLicensingMerck KGaAOncologyPDS BiotechnologyPharmaceuticalResearch

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

Adding cetuximab following colon cancer surgery does not improve disease-free survival

04-04-2012

Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

1 to 25 of 31 results

Back to top